Nexalin Technology Inc. announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry evaluating its Deep Intracranial Frequency Stimulation (DIFS™) technology for the treatment of Attention Deficit Hyperactivity Disorder $(ADHD)$ in adults. The study found that four weeks of non-invasive DIFS™ neurostimulation was associated with significant improvements in attention, reductions in ADHD symptoms, and improvements in mood and sleep quality. These clinical outcomes were supported by objective changes in brain activity, as measured by electroencephalography (EEG) and magnetoencephalography $(MEG)$. The treatment was well tolerated, with a safety profile comparable to sham stimulation and no serious adverse events reported. The results have already been published and presented in the journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624980-en) on January 14, 2026, and is solely responsible for the information contained therein.